These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 11842386)

  • 41. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
    Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
    Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
    J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of rituximab-CHOP therapy on clinical course and autoimmune parameters in rheumatoid arthritis associated with diffuse large B cell non-Hodgkin lymphoma.
    Vujasinovic-Stupar N; Pejnovic N; Markovic O; Babic G
    Ann Hematol; 2008 Sep; 87(9):767-9. PubMed ID: 18386008
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
    Czuczman MS
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The successful treatment of primary cardiac lymphoma with a dose-dense schedule of rituximab plus CHOP.
    Dawson MA; Mariani J; Taylor A; Koulouris G; Avery S
    Ann Oncol; 2006 Jan; 17(1):176-7. PubMed ID: 16157624
    [No Abstract]   [Full Text] [Related]  

  • 49. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
    Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M;
    Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients.
    Guyot A; Ortonne N; Valeyrie-Allanore L; Bagot M
    Arch Dermatol; 2010 Jan; 146(1):89-91. PubMed ID: 20083704
    [No Abstract]   [Full Text] [Related]  

  • 51. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
    Voso MT; Pantel G; Weis M; Schmidt P; Martin S; Moos M; Ho AD; Haas R; Hohaus S
    Br J Haematol; 2000 Jun; 109(4):729-35. PubMed ID: 10929022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Fabbri A; Gozzetti A; Rigacci L
    Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
    [No Abstract]   [Full Text] [Related]  

  • 54. Rituximab and chemotherapy in diffuse large B-cell lymphoma.
    Sonet A; Bosly A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):719-26. PubMed ID: 19496708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
    Miles SA; McGratten M
    J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
    [No Abstract]   [Full Text] [Related]  

  • 56. CHOP and rituximab in elderly patients.
    Portlock CS
    Curr Oncol Rep; 2002 Sep; 4(5):414. PubMed ID: 12162916
    [No Abstract]   [Full Text] [Related]  

  • 57. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
    J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma.
    Shimada K; Kosugi H; Narimatsu H; Shimada S; Suzuki T; Ito M; Kinoshita T; Mori N; Naoe T
    J Clin Exp Hematop; 2008 Apr; 48(1):25-8. PubMed ID: 18434690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
    Tobinai K
    Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas.
    Held G; Schubert J; Reiser M; Pfreundschuh M;
    Semin Hematol; 2006 Oct; 43(4):221-9. PubMed ID: 17027656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.